Live price temporarily unavailable.
AN2 Therapeutics (ANTX) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Operating income | −$21.6M | −$42.3M | −$69.6M | −$56.8M | −$38.1M |
| Net income | −$21.5M | −$41.0M | −$64.7M | −$51.3M | −$35.2M |
| EPS (diluted) | −$10.64 | −$2.79 | −$2.74 | −$1.72 | −$1.16 |
| Balance sheet | |||||
| Cash and equivalents | $12.1M | $27.2M | $15.6M | $21.4M | $19.9M |
| Total assets | $65.3M | $102.6M | $138.7M | $92.1M | $62.0M |
| Total liabilities | $3.41M | $7.19M | $14.0M | $10.2M | $8.89M |
| Shareholders' equity | −$47.4M | $95.4M | $124.7M | $81.8M | $53.1M |
| Cash flow | |||||
| Operating cash flow | −$20.5M | −$33.5M | −$53.3M | −$49.3M | −$29.8M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$14.0M | −$8.60M | −$11.5M | −$7.22M | −$10.0M | −$9.32M | −$10.6M | −$8.90M |
| Net income | −$12.7M | −$7.52M | −$10.6M | −$6.46M | −$9.35M | −$8.71M | −$10.0M | −$8.19M |
| EPS (diluted) | −$0.43 | −$0.25 | −$0.35 | −$0.21 | −$0.31 | −$0.29 | −$0.29 | −$0.18 |
| Balance sheet | ||||||||
| Cash and equivalents | $33.5M | $21.4M | $20.0M | $18.2M | $18.0M | $19.9M | $53.5M | $44.3M |
| Total assets | $97.7M | $92.1M | $81.3M | $75.8M | $67.2M | $62.0M | $87.5M | $81.7M |
| Total liabilities | $10.0M | $10.2M | $8.01M | $6.98M | $6.86M | $8.89M | $5.73M | $5.75M |
| Shareholders' equity | $87.7M | $81.8M | $73.3M | $68.8M | $60.4M | $53.1M | $81.8M | $75.9M |
| Cash flow | ||||||||
| Operating cash flow | −$12.0M | −$5.27M | −$10.6M | −$7.60M | −$6.38M | −$5.24M | −$12.1M | −$7.00M |
From AN2 Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning AN2 Therapeutics in our feed yet.